AlphAIalphai — Financial news for AI agents
Investing.comMAR 163 min read$PROF

Profound Medical stock rating reiterated by Raymond James on trial data

Raymond James has reiterated an Outperform rating and an $11.00 price target for Profound Medical Corp. (NASDAQ:PROF) following strong 6-month data from its CAPTAIN trial. The firm anticipates similar robust 12-month outcomes, supporting the commercial momentum of the TULSA procedure. Despite a recent stock dip, the company shows significant revenue growth and is considered undervalued by InvestingPro, with analyst targets ranging from $11 to $13.

Original reporting
Investing.com · Analyst Ratings
Published Mar 16, 2026, 8:36 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 16, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$PROF
Bullish
high confidence
Mentioned
$PROF
alphai data visualization · based on Investing.com
Decision brief

The 30-second read

$PROFBullishHigh
01

Why it matters

The reaffirmed analyst rating and trial success could catalyze short-term buying interest, potentially driving the stock price upward.

02

Market read

The news is highly relevant for investors interested in biotech and medical device sectors, especially those focusing on prostate health innovations.

03

What to watch

Potential delays in trial outcomes or regulatory hurdles could negatively impact stock performance, which are not reflected in current analysis.

Timing: Immediate, as news is recent and market reaction is likely soon.

Background

Profound Medical is developing minimally invasive treatments for prostate conditions, with recent positive trial data bolstering its market prospects.

Company-level read

Ticker impact

$PROFBullishHigh confidence
Context

High relevance due to recent analyst upgrade and trial data impact.

Expected impact

Moderate upward movement (~5-10%) in the near term, contingent on market reaction to the reaffirmation and trial data.

Evidence & confidence

Strong trial data and analyst support increase confidence in the company's growth trajectory, especially given the undervaluation indicated by analyst targets.

Market effects

Sector

Potential positive impact on the medical device and life sciences sectors due to increased investor interest.

Regional

Primarily US-based, with possible influence on related regional markets depending on investor exposure.

Global

Limited, as the news pertains to a specific company's trial data and analyst rating.

Counterpoint

What could challenge this read

The stock may have already priced in the positive trial data and analyst support, leading to limited upside potential.

Key entities

  • Company
    Profound Medical Corp.

    A medical device company specializing in prostate treatment technologies.

  • Financial Institution
    Raymond James

    An investment bank and financial services company providing analyst ratings.

Read at source← All news

Related articles

AUG 6
$PROFMed

Profound Medical Corp. (PROF): Results of Operations and Financial Condition

Profound Medical Corp. (PROF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Profound Medical Reports Second Quarter 2026 Financial Results – Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early

SEC EDGAR 8-K6 min
AUG 15
$KBRMedAI 8/10

KBR’s planned Trinzic spin-off secures $208 million U.S. Army task order supporting Hellfire, JAGM, Javelin and TOW weapons

KBR said it secured a $208 million U.S. Army cost-plus-fixed-fee task order under OASIS+ for support tied to the TAGM portfolio, including Hellfire, JAGM, Javelin and TOW, plus Hydra rockets and Long-Range Precision Munitions. Work spans engineering, prototyping, modernization, foreign military sales and logistics across the weapons lifecycle.

defence-industry.eu3 min
AUG 15
$HNGEMed

Jim Cramer says one stock hitting new highs is still a screaming buy

Jim Cramer reiterated a triple buy call on Hinge Health (HNGE) on “Mad Money” Aug. 11. The stock hit a new all-time high of $93.13 on Aug. 10 and is up about 85.83% YTD, per Yahoo Finance. Hinge reported Q2 2026 revenue of $213 million (+53% YoY), free cash flow of $99.6 million, and raised FY guidance to $856-$860 million. It also agreed to a $105 million cash acquisition (Cylinder Health) to expand into GI care.

yahoo.com6 min
AUG 15
$NVDAMed

Nvidia scales back funding guarantee for Ohio OpenAI data center, WSJ reports

Reuters, citing the WSJ, says Nvidia scaled back its funding guarantee for a proposed OpenAI data center in Ohio. Nvidia is expected to initially guarantee less than $120 billion versus $250 billion previously discussed, covering only the first phase. A deal could be signed as soon as this weekend. OpenAI and Nvidia are nearing agreement; SB Energy (SoftBank unit) would develop the 10 GW site.

lufkindailynews.com2 min